IL6 and chronic kidney disease: Crucially, these nontraditional drivers exhibit stage-dependent escalation—severe CKD demonstrates 4.2-fold higher IL-6 and 3.6-fold greater F2-isoprostanes than moderate CKD [45], mechanistically explaining the attenuated efficacy of isolated LDL-C lowering in advanced stages [42].